Zoetis Future Growth

Future criteria checks 2/6

Zoetis is forecast to grow earnings and revenue by 8.1% and 6.4% per annum respectively. EPS is expected to grow by 8.9% per annum. Return on equity is forecast to be 43.1% in 3 years.

Key information

8.1%

Earnings growth rate

8.9%

EPS growth rate

Pharmaceuticals earnings growth	21.0%
Revenue growth rate	6.4%
Future return on equity	43.1%
Analyst coverage	Good
Last updated	16 Apr 2024

Recent future growth updates

Recent updates

Zoetis rises on 2023 revenue forecast above estimates, Q4 profit in-line with consensus

Feb 14

Zoetis Is An Awesome Dividend Growth Stock

Jan 17

It's A Great Time To Buy Zoetis Shares

Jan 10

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Jan 03

Is Zoetis (NYSE:ZTS) Using Too Much Debt?

Dec 29

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Dec 14

Zoetis raises quarterly dividend by 15.4% to $0.375/share

Dec 08

Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Nov 20

Zoetis' Q3 Earnings: Supply Issues Putting A Dent On Growth

Nov 08

Zoetis Q3 2022 Earnings Preview

Nov 02

Does Zoetis (NYSE:ZTS) Deserve A Spot On Your Watchlist?

Nov 02

Zoetis declares $0.325 dividend

Oct 13

A Rising Dollar May Mean Lower Zoetis Shares

Oct 07

Is Zoetis (NYSE:ZTS) Using Too Much Debt?

Sep 15

Zoetis cleared to acquire Jurox in Australia subject to divestiture

Sep 15

Zoetis acquires Scottish animal health digital tech business

Sep 05

Are Investors Undervaluing Zoetis Inc. (NYSE:ZTS) By 21%?

Aug 19

Zoetis: Strong Q2 Underlying Growth But Hit By Strong U.S. Dollar

Aug 12

Zoetis Q2 2022 Earnings Preview

Aug 03

Zoetis: Lovable Company With Vision

Jul 20

Earnings and Revenue Growth Forecasts

NYSE:ZTS - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	10,469	3,009	2,700	3,424	14
12/31/2025	9,822	2,775	2,430	3,207	16
12/31/2024	9,169	2,533	2,104	2,858	16
12/31/2023	8,544	2,344	1,621	2,353	N/A
9/30/2023	8,371	2,280	1,492	2,197	N/A
6/30/2023	8,222	2,213	1,285	1,999	N/A
3/31/2023	8,094	2,071	1,458	2,152	N/A
12/31/2022	8,080	2,114	1,326	1,912	N/A
9/30/2022	8,007	2,067	1,267	1,850	N/A
6/30/2022	7,995	2,090	1,429	1,977	N/A
3/31/2022	7,891	2,073	1,607	2,122	N/A
12/31/2021	7,776	2,037	1,736	2,213	N/A
9/30/2021	7,616	1,982	1,791	2,252	N/A
6/30/2021	7,412	1,909	1,702	2,161	N/A
3/31/2021	7,012	1,774	1,682	2,118	N/A
12/31/2020	6,675	1,638	1,673	2,126	N/A
9/30/2020	6,542	1,663	1,523	1,990	N/A
6/30/2020	6,340	1,617	1,456	1,934	N/A
3/31/2020	6,339	1,611	1,323	1,814	N/A
12/31/2019	6,260	1,500	1,335	1,795	N/A
9/30/2019	6,150	1,461	1,365	1,797	N/A
6/30/2019	6,046	1,375	1,463	1,841	N/A
3/31/2019	5,914	1,388	1,442	1,790	N/A
12/31/2018	5,825	1,428	1,452	1,790	N/A
9/30/2018	5,721	1,164	1,531	1,814	N/A
6/30/2018	5,588	1,115	1,446	1,703	N/A
3/31/2018	5,442	978	1,381	1,616	N/A
12/31/2017	5,307	864	1,122	1,346	N/A
10/1/2017	5,124	937	N/A	1,024	N/A
7/2/2017	5,018	878	N/A	824	N/A
4/2/2017	4,957	855	N/A	781	N/A
12/31/2016	4,888	821	N/A	713	N/A
10/2/2016	4,885	689	N/A	705	N/A
7/3/2016	4,858	639	N/A	670	N/A
4/3/2016	4,825	378	N/A	655	N/A
12/31/2015	4,765	339	N/A	664	N/A
9/27/2015	4,811	443	N/A	773	N/A
6/28/2015	4,807	420	N/A	672	N/A
3/29/2015	4,790	593	N/A	709	N/A
12/31/2014	4,785	583	N/A	626	N/A
9/28/2014	4,719	562	N/A	537	N/A
6/29/2014	4,612	527	N/A	548	N/A
3/30/2014	4,568	519	N/A	377	N/A
12/31/2013	4,561	504	N/A	681	N/A
9/29/2013	4,483	389	N/A	693	N/A
6/30/2013	4,399	420	N/A	653	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZTS's forecast earnings growth (8.1% per year) is above the savings rate (2.3%).

Earnings vs Market: ZTS's earnings (8.1% per year) are forecast to grow slower than the US market (14.5% per year).

High Growth Earnings: ZTS's earnings are forecast to grow, but not significantly.

Revenue vs Market: ZTS's revenue (6.4% per year) is forecast to grow slower than the US market (8.1% per year).

High Growth Revenue: ZTS's revenue (6.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ZTS's Return on Equity is forecast to be very high in 3 years time (43.1%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Zoetis Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Zoetis Inc. Provides Earnings Guidance for the Full Year 2023

Zoetis Inc. Maintains Earnings Guidance for the Full Year 2023

Zoetis Inc. Provides Earning Guidance for Full Year 2023

Zoetis Inc. Provides Earnings Guidance for the Full Year 2022

Zoetis Inc. Provides Earnings Guidance for the Full Year 2022

Recent updates

Zoetis Inc. Announces Executive Changes

Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment

Now 22% undervalued after recent price drop

Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit

Zoetis Inc., Annual General Meeting, May 22, 2024

Upcoming dividend of US$0.43 per share

Zoetis Inc. Appoints Gavin D.K. Hattersley to Its Board of Directors

Zoetis: My Favorite Healthcare Stock Right Now

Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness

CEO & Director notifies of intention to sell stock

CEO & Director exercised options and sold US$3.6m worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Dividend of US$0.43 announced

Zoetis Inc. Declares Second Quarter 2024 Dividend, Payable on June 4, 2024

Upcoming dividend of US$0.43 per share at 0.9% yield

Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns

Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E

Insufficient new directors

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Zoetis Inc. Declares Dividend for the First Quarter of 2024, Payable on March 1, 2024

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

CEO & Director exercised options and sold US$1.7m worth of stock

Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today

Zoetis: High-Quality Compounder With A Reasonable Price After Earnings

Zoetis Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now

Upcoming dividend of US$0.38 per share at 0.9% yield

Zoetis Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 1, 2023

Zoetis Is An Impressive Healthcare Compounder

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Executive VP notifies of intention to sell stock

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH.

Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly

CEO & Director exercised options and sold US$1.7m worth of stock

Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.

Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zoetis: My Dog Approves Of This Dividend Compounder

Upcoming dividend of US$0.38 per share at 0.9% yield

Zoetis Inc. Announces Appointment of Ester Banque as Executive Vice President and President, U.S. Operations

Zoetis: A Purrfect Addition To Your Portfolio

Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?

CEO & Director notifies of intention to sell stock

JAB Holdings B.V. acquired an unknown majority interest in Pumpkin Insurance Services Inc. from Zoetis Inc. (NYSE:ZTS).

Zoetis Inc. Declares Dividend for Third Quarter of 2023, Payable on September 1, 2023

Zoetis Inc. Announces U.S. Food and Drug Administration Approves Librela™ (Bedinvetmab Injection) for Control of Pain Associated with Osteoarthritis in Dogs

Zoetis Inc. Maintains Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Key Executive exercised options and sold US$417k worth of stock

These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well

Upcoming dividend of US$0.38 per share at 0.9% yield

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

CEO & Director exercised options and sold US$2.0m worth of stock

Zoetis Inc. Provides Earning Guidance for Full Year 2023

Full year 2022 earnings: EPS misses analyst expectations

Zoetis rises on 2023 revenue forecast above estimates, Q4 profit in-line with consensus

Zoetis Inc. Declares Second Quarter 2023 Dividend, Payable on June 1, 2023

Zoetis Inc. Announces Termination of Glenn David as Executive Vice President and Group President, U.S. Operations

Zoetis Is An Awesome Dividend Growth Stock

Upcoming dividend of US$0.38 per share

It's A Great Time To Buy Zoetis Shares

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Is Zoetis (NYSE:ZTS) Using Too Much Debt?

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Zoetis Inc. Declares Dividend for the First Quarter of 2023 Dividend, Payable on March 1, 2023

Zoetis raises quarterly dividend by 15.4% to $0.375/share

Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)